<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305474</url>
  </required_header>
  <id_info>
    <org_study_id>XYMHI001</org_study_id>
    <nct_id>NCT00305474</nct_id>
  </id_info>
  <brief_title>Identification and Treatment of the Liability to Develop Schizophrenia</brief_title>
  <official_title>Identification and Treatment of the Liability to Develop Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <brief_summary>
    <textblock>
      This study seeks to determine whether adult, non-psychotic, first-degree relatives of
      schizophrenic patients who show specific neurocognitive deficits and negative symptoms will
      show improvements in these areas following a 6-month, double-blind trial of a low dose (up to
      2.0 mg) of risperidone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological - cognitive measures</measure>
    <time_frame>2003-2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Symptoms</measure>
    <time_frame>2003-2010</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having at least one first-degree biological relative with schizophrenia and their age
             is between 19 and 59.

          -  Desire to participate in a medication trial.

          -  Is able to provide informed consent.

          -  Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on
             the Scale for the Assessment of Negative Symptoms (SANS).

          -  Scoring two or more standard deviations below normal in at least one of three
             cognitive domains: vigilance/working memory, long-term verbal memory, and executive
             functions.

          -  Scoring at least one standard deviation below normal in a second cognitive domain.

        Exclusion Criteria:

          -  IQ less than 80.

          -  Formal education less than 10 years.

          -  History of psychotic disorders.

          -  History of treatment with an antipsychotic medication.

          -  A substance abuse diagnosis within 6 months of diagnosis.

          -  A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent
             cognitive deficits).

          -  A history of neurologic disease or damage.

          -  A medical condition with significant cognitive sequelae.

          -  A history of electroconvulsive treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Stone, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lingjiang Li, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Central South Unversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lingjiang Li, MD, PhD</last_name>
    <phone>011-86-731-555-0413</phone>
    <email>lilj9016@public.cs.hn.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liwen Tan, MD, PhD</last_name>
    <phone>011-86-13874870034</phone>
    <email>gangbie7788@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mental Health Institute</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liwen Tan, MD, PhD</last_name>
      <phone>01186-13874870034</phone>
      <email>gangbie7788@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Liwen Tan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ning Ma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>You Yin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenjuan Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Wan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Zhang, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>June 23, 2009</last_update_submitted>
  <last_update_submitted_qc>June 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>William Stone, PhD</name_title>
    <organization>Beth Israel- Deaconess Medical Center</organization>
  </responsible_party>
  <keyword>Negative symptoms</keyword>
  <keyword>neuropsychological deficits</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>diagnostic</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

